Dr Vivian Hope. Health Protection Agency, London. 19 th Annual Conference of the British HIV Association (BHIVA)

Similar documents
Mr James McVeigh Liverpool John Moores University

HIV and injecting drug use in the UK

Harm Reduction Database Wales: Needle and Syringe provision

HIV Risk Behaviour in Irish Intravenous Drug Users

Primary Care Services for blood borne viral hepatitis prevention, treatment and care

Detection of Hepatitis B and C in Primary Care

AUSTRALIAN NSP SURVEY

JSNA Substance Misuse

Promoting hepatitis B vaccination

Addiction and Substance misuse pathways

An audit of hepatitis C services in prisons. Clare Humphreys Consultant in Health Protection Public Health England

New South Wales Needle and Syringe Program Enhanced Data Collection

Signs of success latest national NESI data?

PERFORMANCE AND IMAGE ENHANCING DRUGS

Poland nationalupdate

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

HIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015

Hepatitis C Strategy. About us. What is hepatitis C?

Models of good practice in drug treatment in Europe. Project group

Blood-borne viruses in marginalised populations

AUSTRALIAN NSP SURVEY NATIONAL DATA REPORT

HIV testing in black Africans living in England

Substance use among year olds in the UK: Key findings from the 2011 European Survey Project on Alcohol and Drugs (ESPAD)

Offering Testing for Hepatitis B and C in Primary Care. Presentation 3. October 2017

Notes Detection of Hepatitis B and C in Primary Care

Notes Offering Testing for Hepatitis B and C in Primary Care

Latest Shooting Up report focuses on the changing nature of injecting drug use

Notes Offering Testing for Hepatitis B and C in Primary Care

PH52. Audit tool for the implementation of. NICE public health guidance 52 Needle and syringe programmes

Item 4. Sexual Health and Blood Borne Virus Strategy Strategy for Sexual Health and Blood Borne Viruses. Background

The impact of economic recession on drug users and drug treatment

Guidelines For Services Providing Injecting Equipment

I TRACK Survey. Report June 1, 2006

Greater Glasgow and Clyde. Blood Borne Viruses: Some important basic facts

Detection of Hepatitis B and C in Primary Care. Presentation 2. October 2017

BROMLEY JOINT STRATEGIC NEEDS ASSESSMENT Substance misuse is the harmful use of substances (such as drugs and alcohol) for non-medical purposes.

New Brunswick Report on Sexually Transmitted and Blood Borne Infections, 2016

Blood Borne Viral Hepatitis Action for Wales Research Programme Developing the evidence base Findings, Implications and Recommendations

Greater Manchester Commissioning Guidelines for Blood Borne Virus Prevention

Question 1. Blood Borne Viruses: Some important basic facts 6. What does BBV stand for? A. Blood Based Virus. B. Blood Borne Viruses

Detection of Hepatitis B and C in Primary Care

The next steps

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

New trends in harm reduction in Europe: progress made challenges ahead

The drugs situation in Ireland: an overview of trends from 2005 to 2015.

Quantifying Problematic Drug Use Within Liverpool and Sefton Drug [and Alcohol] Action Teams (2000/1 and 2001/2)

Hepatitis C What is it? Should I get tested?

Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, : the HITS-p study

overview Blood-borne viral infections among injecting drug users in Ireland, 1995 to 2005 Jean Long Health Research Board

Rachel Rowe, Israel Berger Drug & Alcohol Multicultural Education Centre. Jan Copeland. National Cannabis Prevention and Information Centre

The evolution of the HIV/AIDS outbreak among IDUs in Romania

Substance Misuse Treatment Framework (SMTF) Service Framework for Needle and Syringe Programmes in Wales

Evaluation of the Peer to Peer Project. May 2007

Routine blood- borne virus testing for HIV, hepatitis B & C in the emergency department: the new normal?

HIV testing in England and the NICE Quality Standards

Most recent data, analyses and feed-back from the 2016 DRID national updates

Hepatitis C in the UK Report

Hepatitis C - Are we doing enough to diagnose, test and refer for treatment in primary care? Lonsdale Medical Centre a case example

Statistics from the Northern Ireland Drug Misuse Database: 1 April March 2011

Part of the Continuum of Care. Harm Reduction. Gino Vumbaca President Harm Reduction Australia

Two decades of successes and failures in controlling the transmission of HIV through injecting drug use in England and Wales, 1990 to 2011

Methods: respondent driven sampling (RDS) was used to recruit PWID

Hepatitis prevention in the context of HIV prevention point work in Latvia

Substance misuse among young people The data for

The health of prisoners: a focus on infectious diseases.

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

The forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

INTRAVENOUS INJECTING DRUG USE.

Drug situation in Greece

DMRI Drug Misuse Research Initiative

Infectious Diseases and Sexual Health in Southwark

What is Hepatitis C Virus (HCV)?

Building and enhancing capacity for HCV prevention; BC case scenario

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

Thirty years of harm reduction in the Netherlands HCV elimination ahead?

Statistics from the Northern Ireland Drug Misuse Database: 1 April March 2012

Prevention of and Immunisation against Hepatitis B and C

United-Kingdom United Kingdom Drug Report 2018

NI Regional Hepatitis B&C Managed Clinical Network Annual Report 2017

Statistics from the National Drug Treatment Monitoring System (NDTMS) 1 April March 2012

High prevalence and incidence of HIV and HCV among new injecting drug users with a large proportion of migrants Is prevention failing?

Background: Kirketon Road Centre

Strategies of drug users to avoid infection with hepatitis C

Analysis of Greater Glasgow & Clyde IEP Data John Campbell

Needle Syringe Program National Minimum Data Collection. Data Dictionary

What is injection drug use?

Epidemiology of different hepatides (B & C) in Lithuania

Prevention of and Immunisation against Hepatitis B and C

Technical Guidance Note for Global Fund HIV Proposals

Integrated harm reduction services for drug users and homeless people. Katrin Schiffer

Statistics on Drug Misuse: England, 2009

Prevalence of HIV and hepatitis infections in the United Kingdom

Dr. dr. Diah Setia Utami, SpKJ, MARS Deputy of Rehabilitation Narcotic National Board of Republic of Indonesia

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

S u b s t a n c e M i s u s e

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

Chronic Hepatitis C The Patient s Perspective

Statistics on Drug Misuse: England, 2007

Ecstasy and Related Drugs Reporting System drug trends bulletin April 2014

Transcription:

19 th Annual Conference of the British HIV Association (BHIVA) Dr Vivian Hope Health Protection Agency, London 16-19 April 2013, Manchester Central Convention Complex

Prevalence of, and risk factors for, human immunodeficiency virus, hepatitis B and hepatitis C infections among men who inject image and performance enhancing drugs in England & Wales. Dr Vivian Hope Centre for Infectious Disease Surveillance and Control, Public Health England. With: A Marongiu, Dr F Ncube, S Croxford, & Prof JV Parry, Public Health England. Dr J McVeigh, Dr C Beynon, Prof M Bellis, Centre for Public Health, Liverpool John Moores University. J Smith, Public Health Wales. M Evans-Brown, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. A Kimegård, Department of Public Health, Aarhus University, Denmark.

IPEDs are used to change physical appearance or improve performance / strength. This sub-group of people who inject drugs (PWID) is rarely studied. Anabolic steroids (AS) are probably the most commonly used type of IPED. Drug (2011/12) Last year Ever Anabolic steroids 70,000 228,000 Heroin 47,000 255,000 Image and Performance Enhancing Drug (IPED) Injecting British Crime Survey, 2012 All & new clients attending agency based Needle and Syringe Programmes (NSPs) in Cheshire & Merseyside: 1991-2011.

Recruitment & the sample Sample recruited as part of Unlinked Anonymous Monitoring (UAM) Survey of PWID. Which monitors the prevalence of blood borne viruses (BBVs) among injectors of psychoactive drugs attending collaborating specialist services. Between June 2010 & May 2011 collaborating NSP services (17 across England and two in Wales) recruited IPED users. Those who agreed to take part provided an oral fluid sample and selfcompleted a short questionnaire on IPED use. Overall, 410 individuals took part in the survey. Five women and 10 participants who did not report any injecting were excluded. Analyses thus focused on the 395 male IPED injectors. IPED Injectors Male psychoactive drug injectors: UAM Survey 2011 Median age (IQR), Mean age 28 (13), 30.6 35 (11) 35.3 Had ever been in prison 16% 78%

Reported IPED Use Proportion having done so Reported injecting IPEDs for less than 5 years 48% 141* Had used 3 types of IPED during the preceding year 34% 133 IPED: Oral use Anabolic Steroids 57% 226 Anti-oestrogens 23% 92 Ephedrine 20% 78 Others reported by 5%: Clenbuterol & Thyroid hormones. IPED: Injected Anabolic Steroids 86% 340 Growth Hormone 32% 128 Human chorionic gonadotropin (hcg) 16% 62 Others reported by 5%: Insulin & Melanotan I / II * Could not be calculated for all due to missing data on age or age of first injection. n

Psychoactive drug use, injecting practice, and related problems Psychoactive drug use Snorted cocaine, last year Taken amphetamine, last year Ever injected illicit psychoactive drug Injecting practice Ever shared needle, syringe or vial Subcutaneous injection in the last year Intramuscular injection in the last year Reported being injected by someone else Injecting related problems Abscess/open wound Redness, tenderness or swelling 12% 5% 9% 17% 7% 39% 46% 43% 88% 0% 20% 40% 60% 80% 100%

Sexual behaviours Proportion having done so n Male sexual partner(s), last year 3.3% 13 Two or more sexual partners (male & female), last year Looking at just female partners: 20% (80) reported 5 partners, 8% (33) reported 10 partners 47% 187 Always condom for anal/vaginal sex, or no sex, last year 20% 78 Reported use of a phosphodiesterase type 5 inhibitor ( Viagra / Calias ) 6.6% 26 Among the male injectors of psychoactive drugs taking part in the UAM Survey in 2011:- 34% had one partner in last year, 36% more than one partner, and 29% had not had sex.

Health Service Usage Intervention uptake: Ever had a blood test for HIV 31% Ever had a blood test for hepatitis C One or more doses hepatitis B vaccine 22% 23% Medicine use in last year: Used medication prescribed by a doctor 28% Services used in last year: Had used a GUM/sexual health/sti clinic Had used an A&E/Walk-in 17% 16% Had seen a GP about their health 45% 0% 20% 40% 60%

Markers of BBV infection Note: Oral Fluid sample test sensitivity for anti-hbc is 75% and anti-hcv 92%. Multivariable analyses indicated that having:- anti-hiv was associated with: age, having ever had abscess/open wound, use of GUM/sexual health/sti clinic, and having sex with men. anti-hbc was associated with: subcutaneous injection and use of GUM/sexual health/sti clinic. anti-hcv was associated with: the injection of psychoactive drugs and taking phosphodiesterase type 5 inhibitors ( Viagra / Cialis ). Among the male injectors of psychoactive drugs taking part in the UAM Survey in 2011: 45% (95%CI 43%- 48%) had anti-hcv; 16% (95%CI 14% -18%) had anti-hbc; 1.4% (95% CI 0.88% -2.2%) had anti-hiv.

Summary & Conclusions The findings of this, the largest study of BBVs among IPED injectors, need to be generalised with caution. However, they indicate: 1 in 18 IPED injectors have been exposed to hepatitis C; 1 in 11 to hepatitis B; and 1 in 65 have HIV. The HIV prevalence is similar to that among injectors of psychoactive drugs. BBV testing uptake is low, with about a fifth ever tested for hepatitis C, and almost one-third for HIV. The only previous UK prevalence study, undertaken in the 1990 s as part of the UAM Survey, found no HIV. It did find anti-hbc, but the prevalence was about a quarter of that found in this new study. This previous study had not looked at hepatitis C. The findings suggest that level of infection may have increased. IPED injectors sexual behaviours and psychoactive drug use are probably putting them at risk of BBV infection. Their IPED injection practices also pose a risk. Interventions are needed to target these behaviours. Those providing voluntary confidential testing services and care related to HIV should be alert to the use, and injection, of IPEDs.

Acknowledgements We would like to thank: all the people who took part in the survey, the collaborating NSP services, and the staff who processed and tested the oral fluid samples, those who entered the questionnaire data, and the support staff who assisted with this survey.

#BHIVA2013